ArticleJournal of laboratory and precision medicine2020
Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease.
Article in Journal of laboratory and precision medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Impact of Microbial Composition on Postprandial Glycaemia and Lipidaemia: A Systematic Review of Current Evidence.Nutrients · 2021Pooled it
- Effects of a diet based on the Dietary Guidelines on vascular health and TMAO in women with cardiometabolic risk factors.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2022Trial
- Evaluation of an 8-Week Vegan Diet on Plasma Trimethylamine-N-Oxide and Postchallenge Glucose in Adults with Dysglycemia or Obesity.The Journal of nutrition · 2021Trial
- Sex differences in the gut microbiome and related metabolites: role in cardiometabolic disease.Gut microbes · 2026Review
- Gut microbiota‑derived metabolites in cardiovascular disease: Focus on trimethylamine N‑oxide, short‑chain fatty acids and bile acids (Review).Molecular medicine reports · 2026Review
- Utility of trimethylamine N-oxide (TMAO) as a biomarker for risk stratification in chronic kidney disease: a multicenter observational study.BMC nephrology · 2025Observational
- Article
- A Systemic Perspective of the Link Between Microbiota and Cardiac Health: A Literature Review.Life (Basel, Switzerland) · 2025Review
- Article
- Review
- Interactions between the gut microbiome, associated metabolites and the manifestation and progression of heart failure with preserved ejection fraction in ZSF1 rats.Cardiovascular diabetology · 2024Article
- Breaking bugs: gut microbes metabolize dietary components and modulate vascular health.Critical reviews in food science and nutrition · 2024Review
- Gut microbiota's causative relationship with peripheral artery disease: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Adipokines and Bacterial Metabolites: A Pivotal Molecular Bridge Linking Obesity and Gut Microbiota Dysbiosis to Target.Biomolecules · 2023Review
- Multi-omics analysis identifies potential mechanisms by which high glucose accelerates macrophage foaming.Molecular and cellular biochemistry · 2023Article
- Gut-brain axis: Mechanisms and potential therapeutic strategies for ischemic stroke through immune functions.Frontiers in neuroscience · 2023Review
- Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status.Neurobiology of disease · 2022Article
- Gut microbiota metabolic characteristics in coronary artery disease patients with hyperhomocysteine.Journal of microbiology (Seoul, Korea) · 2022Article
- Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study.Diagnostics (Basel, Switzerland) · 2022Article
- Gut Metabolite Trimethylamine N-Oxide Protects INS-1 β-Cell and Rat Islet Function under Diabetic Glucolipotoxic Conditions.Biomolecules · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Host-microbes interaction plays a crucial role in cardiovascular disease (CVD) pathogenesis, mechanistically via metaorganismal pathways. The trimethylamine N-oxide (TMAO) metaorganismal pathway is the most deeply investigated one, which comprises trimethylamine precursors, such as choline, trimethylamine lyase, trimethylamine, host liver FMO3, TMAO, and downstream effectors involving unfolded protein response (UPR), NF-κB and NLRP3 inflammasome. Accumulating data from clinical investigations of CVD patient cohorts and rodent models have supported the critical role of this metaorganismal pathway in the pathogenesis of CVD. We summarize an array of significant animal studies especially for arthrosclerosis with an emphasis on downstream molecular effectors of this metaorganismal pathway. We highlight clinical investigations of the prognostic value of plasma TMAO levels in predicting prospective risk for future major adverse cardiac events (MACE) indicated by composite end points of myocardial infarction (MI), stroke, heart failure (HF), other ischemic cardiovascular events, or death. Further, we discuss the latest advances of preclinical models targeting the gut microbiota trimethylamine lyase of the TMAO metaorganismal pathway for CVD intervention, as well as the catalog of gut microbiota TMA lyase genes and microbes in the human gut as the prerequisite for potential clinical intervention. In-depth characterization of TMAO metaorganismal pathway holds great promise for CVD clinical metagenomics, diagnostics and therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.